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ABSTRACT
Introduction There is a global interest in cancer 
immunotherapy. Clinical trials have found that one group, 
immune checkpoint inhibitors (ICIs), has demonstrated 
clinical benefits across various cancers. However, 
research focused on the experiences of people affected 
by cancer who have undergone this treatment using 
qualitative methodology is currently limited. Moreover, 
little is known about the experiences and education needs 
of the healthcare staff supporting the people receiving 
these immunotherapies. This study therefore seeks to 
explore the experiences of using ICIs by both the people 
affected by cancer and the healthcare professionals 
who support those people, and use the findings to make 
recommendations for ICI supportive care guidance 
development, cancer immunotherapy education materials 
for healthcare professionals, cancer policy and further 
research.
Methods and analysis Patient participants (n=up to 30) 
will be recruited within the UK. The sample will incorporate 
a range of perspectives, sociodemographic factors, 
diagnoses and ICI treatments, yet share some common 
experiences. Healthcare professionals (n=up to 15) 
involved in supporting people receiving immunotherapy 
will also be recruited from across the UK. Data will be 
generated through in- depth, semistructured interviews. 
Reflexive thematic analysis will be used to obtain 
thorough understanding of individual’s perspectives on, 
and experiences of, immunotherapy. Study dates are as 
follows: December 2019–March 2022.
Ethics and dissemination The research will be 
performed in accordance with the UK Policy for Health 
and Social Care Research and Cardiff University’s 
Research Integrity and Governance Code of Practice 
(2018). The study received ethical approval from the West 
Midlands and Black Country Research Ethics Committee 
in October 2019. Health Research Authority and Health 
and Care Research Wales approvals were confirmed in 
December 2019. All participants will provide informed 
consent. Findings will be published in peer- reviewed 
journals, non- academic platforms, the Macmillan Cancer 
Support website, disseminated at relevant national and 
international conferences and presented via a webinar. The 
study is listed on the National Institute for Health Research 
(NIHR) Clinical Research Network Central Portfolio.
INTRODUCTION
Globally, the rapidly evolving field of cancer 
immunotherapy1 is substantially transforming 
outcomes for some people with advanced 
solid and haematological cancers. As popu-
lations age and grow, cancer detection 
Strengths and limitations of this study
 ► Few qualitative studies have explored people’s ex-
periences of immunotherapy and its associated 
supportive care, with no studies exploring these 
experiences known to be reported in the UK context.
 ► This original qualitative study has been designed to 
build on existing knowledge derived predominantly 
from clinical trials and capture rich, detailed insight 
into aspects of individual’s experiences of cancer 
immunotherapy in the UK to develop suggestions for 
improving person- centred care from those receiv-
ing, prescribing and supporting treatments.
 ► This work samples healthcare professionals from 
within and outside oncology, and as a result ex-
plores the unique experiences of professionals who 
are expected to have knowledge and experience of 
managing immune checkpoint inhibitor toxicities 
and providing safe and effective person- centred 
supportive care.
 ► The sample size is appropriate given that qualitative 
research does not search for a representative sam-
ple but to give breadth, depth and rich information 
for analysis. However, there is the possibility of se-
lection bias in that as participants are self- selecting 
they may be particularly motivated to participate in 
the study.
 ► The study coincided with the global COVID-19 pan-
demic and the introduction of physical distancing 
measures in the UK may have an impact on the data 
generated.
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improves and treatments advance, and more people will 
live with cancer.2 3 This, together with the increasing use 
of some immunotherapies earlier in disease trajectories 
as the standard of care, means more people will receive 
these treatments as part of their management pathway. 
However, immunotherapies have risks. Indeed, there is 
real potential for treatment- related adverse events, some 
of which can be severe and even life- threatening.4–6
Arguably, immune checkpoint inhibitors (ICIs), one 
type of cancer immunotherapy, constitute one of the 
most important developments in cancer therapeutics 
in recent years, bringing enhanced survival hope to 
patients with advanced cancer and transforming the 
standard of care.7 8 ICIs include the anticytotoxic T 
lymphocyte antigen-4 (anti- CTLA-4; eg, ipilimumab), 
antiprogrammed cell death-1 (anti- PD-1; eg, nivolumab 
and pembrolizumab) and antiprogrammed cell death-1 
ligand-1 (anti- PD- L1; eg, atezolizumab and durvalumab) 
and monoclonal antibodies, which revive antitumour 
immune responses and restore anticancer immunity by 
targeting immune checkpoints and blocking specific 
proteins in cancer cells which turn the immune system 
off.7 9
Clinical trials of ICIs in people with advanced cancers, 
including, for example, non- small cell lung cancer, 
metastatic and unresectable melanoma and recurrent 
or metastatic head and neck cancer, have demonstrated 
clinical benefits.10–20 Indeed, when evaluated against 
traditional comparator treatments, for example, chemo-
therapy, consistent improvements in progression- free, 
treatment- free and overall survival have been reported in 
both treatment- naive and previously treated patients.10–17 
Furthermore, pembrolizumab and nivolumab main-
tained or even improved quality- of- life (QoL) to a greater 
degree than comparators.18–20
ICIs are usually delivered intravenously within an 
oncology day hospital setting in treatment cycles ranging 
between 2 and 6 weeks and lasting for up to 2 years. As 
the targeting of immune cells generates an autoimmune 
response, immune- related adverse events (irAEs) are 
not uncommon. When used alone (eg, ipilimumab) and 
in combination (eg, ipilimumab and nivolumab), ICIs 
have also produced severe and unique treatment- related 
adverse events,4–6 which are very different to those associ-
ated with traditional cancer therapies and can generate 
a considerable negative impact on individual’s QoL.21 22 
Indeed, patients have reported a range of irAEs including 
endocrine, gastrointestinal, respiratory, dermatological 
and musculoskeletal problems.23 24 Furthermore, by the 
end of 2018, in excess of 13 000 cancer immunotherapy 
irAEs in 18 countries had been reported, with more than 
two- thirds of recorded cases connected with ICIs.25
Compared with the effects of some chemotherapy 
regimens, irAEs may be relatively minor, manageable 
and reversible with timely administration of immune- 
modulating interventions such as corticosteroids. 
However, irAEs can also be unpredictable, severe and 
challenging to manage, arise months after treatment 
initiation,26 persist once treatment has ended and even 
arise several months and years after treatment has been 
completed.27–29 Furthermore, while uncommon, fatali-
ties due to the toxic effects of ICIs have been reported.30 
Indeed, while recognising the limitations of the WHO 
pharmacovigilance database (Vigilyze), a comprehensive 
analysis of entries between 2009 and 2018 identified 613 
fatalities due to ICI irAEs. Most frequently, deaths were 
due to colitis (70% of the anti- CTLA-4 deaths (n=193) 
and 37% of combination therapy (n=87)) and pneu-
monitis (35% of the anti- PD-1/anti- PD- L1 monotherapy 
deaths (n=333)).30
Prioritising the enhancement of peoples’ experiences 
of care, treatment and support, together with meeting 
individual’s needs during treatments and recovery 
are central to the cancer policy commitments of the 
UK’s central and devolved governments.31–33 In phase 
III cancer trials, patient- reported outcomes, notably 
health- related QoL, have provided invaluable insights 
into treatment impact on individuals (see, eg, previous 
studies34–36). Health- related QoL assessment has been 
prominent in multiple ground- breaking international 
phase III randomised controlled trials of checkpoint 
inhibitors.18 37–40 Yet, notwithstanding the positive results 
from many randomised trials, treatment experiences of 
patient populations in real- world settings, as opposed to 
trial settings, may be different. Certainly, given the poten-
tially prolonged nature of immunotherapy treatment 
delivery, together with the possibility of unique immune- 
related adverse events in the short, medium and long 
terms, there is potential for a substantial burden of treat-
ment and ‘collateral damage’ which may adversely impact 
on individual’s lives, health and well- being.
Although the use of ICIs in clinical practice is in its 
infancy, several ICIs have now been approved for treating 
a range of cancers and are used across cancer centres in 
the UK and beyond. The emergence of exciting, new and 
‘cutting edge’ ICI therapies as standard care outside of 
clinical trials has been shown to engender hope and opti-
mism among people with advanced cancers.24 26 41 42 In 
addition, these perceptions may outweigh much of the 
perceived risk of undergoing treatment. Some recipients 
feel sufficiently well and motivated to resume a degree of 
normalcy in their everyday lives.23 However, findings from 
international studies have also highlighted the lasting 
and profound existential- related, social- related, financial- 
related, treatment- related and disease- related uncertain-
ities, adverse effects on physical and emotional health 
and well- being, and a perceived need among some for 
enhanced informational support and guidance.23 24 26 41 42
Shared decision- making, where clinicians support 
patients to share responsibility for decisions, based on 
the best available evidence and considering the strengths 
and risks of various treatment options,43 positively 
affects patients’ treatment experiences44 and 45QoL in 
cancer care. However, it has been noted that existing 
cancer decision- making pathways for some patients 
focus on clinical management of disease rather than 
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patients’ preferences and priorities for cancer treat-
ment.46 Limited literature examines the immunotherapy 
decision- making process, for patients across all tumour 
sites and at various stages of disease. In one study, very few 
patients communicated a good understanding of immu-
notherapy, particularly the potential effectiveness of 
treatment and the possibility of experiencing treatment- 
related side effects.41 Patients receiving immunotherapy 
and their informal carers have also experienced uncer-
tainty related to communication and treatment decision- 
making.24 47 Indeed, patients reported feeling hampered 
by a lack of clear information,23 and carers experienced 
unclear communication regarding immunotherapy 
treatment.47 Findings from a recent study48 indicated 
that most recommendations for ICI treatment were 
made by physicians, though patients generally preferred 
to have the final say regarding treatment commence-
ment. Further enquiry is therefore required to explore 
both patients’ and healthcare professionals’ experiences 
of immunotherapy treatment decision- making in the 
context of the UK.
To the best of our knowledge, there has been no 
published empirical investigation of people’s experiences 
of the ICI treatment journey from a UK perspective. 
Moreover, the experiences of healthcare professionals’ 
who deliver cancer immunotherapy and support people 
receiving these treatments, both within and outside 
specialist oncology settings in the UK, appear to be absent 
from the literature, as are their education and training 
needs. The paucity of existing research within the UK 
context is a concern, for it is a barrier to the effective 
planning and delivery of high- quality safe and effec-
tive person- centred care and support across the cancer 
immunotherapy treatment journey and beyond, particu-
larly as patients experiencing irAEs may present to acute 
medical or emergency department admissions rather 
than oncology services.
Further investigation of patients’ experiences of immu-
notherapy treatment and support, as well as healthcare 
professionals’ experiences of associated care delivery 
and training needs, is therefore imperative to identify 
gaps in knowledge, improve understanding and enhance 
patients’ health outcomes and experiences across care 
settings, and strengthen healthcare professionals’ cancer 
immunotherapy education and training. Furthermore, 
data from a UK perspective are required to ensure contex-
tually relevant immunotherapy education and training 
interventions are developed.
Aim and research questions
This study aims to investigate people’s experiences of ICI 
treatment and associated supportive care and healthcare 
professionals’ experiences of delivering and caring for 
people receiving this treatment. Specifically, it seeks to 
address the following research questions:
1. What are the decision- making experiences of people 
receiving ICI immunotherapy treatment?
2. What are people’s experiences of ICI immunotherapy 
treatment? What are their expectations, concerns, in-
formation and support needs?
3. What are healthcare professionals’ experiences of car-
ing for and supporting patients receiving ICI immuno-
therapy for cancer?
4. What are healthcare professionals’ cancer immuno-
therapy education, training and support needs?
METHODS
Design
To obtain a thorough understanding of individual’s 
perspectives on and experiences of cancer immuno-
therapy as standard care, there is a need to generate 
rich data that has the power to account for and explain 
context and complexity. Thus, an exploratory, qualitative 
approach comprising in- depth interviews and reflexive 
thematic, interpretive analysis49 50 will be used. The use 
of qualitative research will facilitate in- depth exploration 
of individual’s personal and unique views, capturing rich 
and detailed insight into hitherto unexplored aspects 
of individual’s experiences. Furthermore, qualitative 
research is valuable in the investigation of situations that 
are not yet fully understood,51 complex and sensitive.
Research setting and study participants
A purposive sample of up to 30 people affected by cancer 
who are being treated with ICIs will be identified from 
two oncology treatment centres in the UK. The oncology 
treatment centres were selected based on convenience 
sampling, notably existing academic and clinical collab-
orations and networks between Cardiff University and an 
National Health Service (NHS) University Health Board 
and a University Hospital Trust, where it was known that 
immunotherapies were widely delivered, and where 
patients could be recruited reflecting the above variables. 
The sites reflect both urban and rural sociogeographic 
contexts and different treatment settings. Based on expert 
knowledge, it was suggested that these characteristics are 
largely consistent across the immunotherapy treatment 
context in the other UK nations.
Purposive sampling will be utilised to represent a range 
of sociodemographic (eg, age and gender), cancer diag-
noses (eg, lung, melanoma, head and neck, and renal) 
and treatment- related variables (eg, ICIs used as first- line 
and second- line treatments). Purposive sampling and 
recruitment by clinicians during routine consultations 
will ensure representation of people affected by cancer 
regarding their performance status and experience of 
irAEs.
In view of the COVID-19 physical distancing require-
ments to reduce infection risk and following Health 
Research Authority guidance,52 if interested, individuals 
who meet the inclusion criteria (table 1) will be provided 
with a study information pack comprising a letter of invi-
tation, participant information sheet and expression of 
interest researcher contact form, featuring the primary 
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researcher’s phone number and email address so as to 
enable the potential participant to respond directly to 
the researcher. Individuals who decide to participate 
will be asked to contact the primary researcher directly 
either by email or telephone as detailed on the expres-
sion of interest researcher contact form. The researcher 
will subsequently reply to the individual directly either by 
e- mail or by telephone to address any further questions.
If the individual is still interested in participating, study 
documents (participant information sheet, consent form 
and letter of invitation) will again be emailed to ensure 
patients have the correct information, and consent will 
be accepted via electronic completion and signature 
as recommended by the latest NHS Health Research 
Authority guidance52 updated in response to COVID-19. 
Following this, a mutually convenient day, time, place and 
format (by telephone or via a secure video- conferencing 
platform, eg, Microsoft Teams), for the interview will be 
agreed.
Following pilot interviews and to ensure our participants 
have appropriate insights, recruitment of up to 15 regis-
tered nurses, pharmacists and physicians from oncology 
services, primary and secondary care (acute oncology) 
with direct experience of caring for and supporting 
people receiving cancer immunotherapy will proceed 
using a combination of purposive and snowball sampling. 
The sample will include a range of healthcare profes-
sionals including clinical nurse specialists (oncology and 
immunotherapy), oncologists, advanced nurse practi-
tioners, nurse consultants, pharmacists and primary care 
practitioners. Services outside specialist oncology centres 
are considered important as patients often present to 
these services for toxicity management and late onset 
irAEs, including those which arise post- treatment.
Although the sample size of 15 relevant healthcare 
professionals is not large, it will be the in- depth, semi-
structured interview that will enable the team to generate 
rich data, providing meaningful insights into these expe-
riences across various professional groups. In- depth 
qualitative interviews have been considered to be an 
appropriate methodology when looking to generate rich, 
meaningful data based on experiences, and the success 
of this methodology in doing so requires close proximity 
to the human experience under study.53 The term ‘infor-
mation power’ was conceptualised54 as a way to guide 
adequate sample size for qualitative research: the more 
relevant information that the sample holds, the fewer 
participants required. For this study, it is the relevance 
of healthcare professionals’ experience in supporting 
patients undergoing immunotherapy within the sample 
that is considered the key marker of meaning making 
within the qualitative approach.53 54
Owing to COVID-19 physical distancing regulations, 
physicians, registered nurses and pharmacists supporting 
people receiving immunotherapy will initially be recruited 
via targeted online social media, specifically Twitter, using 
existing project networks, and advertising within society 
newsletters and bulletins including the UK Oncology 
Nursing Society. Interested healthcare professionals will 
contact the researcher directly by email. If willing to 
participate and eligible based on the inclusion criteria 
(table 2), a convenient time and preferred interview 
format (telephone or secure, university approved and 
encrypted video- conferencing software such as Microsoft 
Teams) will be arranged. To facilitate snowball sampling, 
interview participants will be asked if they could identify 
known healthcare professionals (physicians, nurses and 
pharmacists) who are directly involved in supporting 
patients undergoing immunotherapy, forward the 
project flyer to these individuals and ask them to contact 
the project researcher by email or telephone if they are 
interested in taking part. Individuals who contact the 
researcher via this sampling method will be also screened 
using the inclusion/exclusion criteria documented in 
table 2. All documents will be emailed and consent will 
be accepted via electronic completion and signature.
Data collection
All data will be generated through in- depth, semistruc-
tured, digitally, audio- recorded interviews. In view of 
COVID-19 physical distancing requirements, to prevent 
Table 2 Inclusion/exclusion criteria for healthcare 
professionals
Inclusion criteria Exclusion criteria
 ► Are registered practitioners 
(nurses, doctors and 
pharmacists) with permanent 
or regular bank contracts
 ► Have experience of working 
with people affected by 
cancer treated with immune 
checkpoint inhibitor 
immunotherapy
 ► Are willing and able to give 
informed consent
 ► Are not registered 
practitioners, or do 
not have permanent or 
regular bank contracts
 ► Do not have experience 
of working with people 
affected by cancer 
treated with immune 
checkpoint inhibitor 
immunotherapy
Table 1 Inclusion/exclusion criteria for people affected by 
cancer
Inclusion criteria Exclusion criteria
 ► Have a confirmed cancer 
diagnosis
 ► Are currently being, or 
have been treated with 
immune checkpoint inhibitor 
immunotherapy in the last 
6 months
 ► Are >18 years of age
 ► Able to participate in a spoken 
interview in English
 ► Are not participating in a 
clinical trial
 ► Are able and willing to give 
informed consent
 ► Are participating in a 
current clinical trial
 ► Demonstrate cognitive 
or psychological 
difficulties that would 
preclude study 
participation
 ► Unable to participate 
in a spoken interview 
in English
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infection and following Health Research Authority guid-
ance,52 interviews will be conducted either by telephone 
or secure video conferencing software (only the audio of 
video interviews will be recorded to protect participant’s 
anonymity). Semistructured interviews allow core topics 
to be raised for discussion, while leaving space and scope 
for the identification and exploration of unforeseen 
issues that may emerge.55 56 All interviews will take place 
in accordance with participants’ preferences. It is antici-
pated that interviews will last up to an hour, although they 
could be longer.
Before commencing interviews, information about the 
study will be confirmed. Participants will have an oppor-
tunity to ask questions and will be informed of their right 
to withdraw at any time without reason or prejudice. If 
a companion is present during an interview, this will be 
respected and facilitated, as this may be advantageous in 
terms of support. Companions’ informed consent will be 
sought and obtained electronically.
Interviews will be conducted by trained researchers 
(SA, SJ,TW) and will commence with open questions 
to develop rapport. Loose interview guides (please see 
online supplemental file) for patients and healthcare 
professionals, developed by the research team, derived 
from the literature review, practice and personal knowl-
edge and scrutinised by the project management team’s 
Patient and Public Involvement (PPI) member, will act as 
aide memoires. The interview guides will use mainly open- 
ended questions.57 To elicit further responses, enrich the 
description and illuminate experiences, prompts will be 
made and clarifications sought when necessary. Prior to 
closing the interview, participants will be given the oppor-
tunity to reflect and add any additional relevant infor-
mation to ensure important aspects not included in the 
interview guide are addressed.
Data analysis
Data collection and analysis will occur simultaneously. 
All interviews will be fully transcribed verbatim by a 
university- approved external transcriber. Files will be 
securely sent via the Cardiff University FastFile applica-
tion. Transcribed data will be analysed using the frame-
work for reflexive thematic analysis devised by Braun and 
Clarke.49 50 This inductive, systematic, analytic approach 
involves searching across the dataset for repeated patterns 
of meaning: data familiarisation, noting early analytical 
observations; generating initial codes, collating codes 
and relevant data extracts; identifying meaningful rela-
tionships between initial codes and developing themes; 
refining, defining and naming themes and subthemes 
in relation to the research aim and objectives. This 
approach to thematic analysis was chosen to enhance the 
transparency and detail of the analysis and to best ensure 
that key patterns and areas of participants’ experiences 
are captured, relative to the study research questions. 
The approach also provides researchers with flexibility 
regarding theoretical approaches that can be applied to 
the data. Table 3 documents how Braun and Clarke’s49 50 
six- step approach to thematic analysis will be applied in 
this study:
Within a constructionist, reflexive approach to thematic 
analysis,50 the process of generating codes, categories 
and themes is influenced by the researcher. Indeed, the 
development and identification of themes is based on the 
researchers’ interpretations and positionality (ie, expe-
rience, background, characteristics and assumptions). It 
is therefore important within this analytic approach to 
outline the process of theme generation. Furthermore, 
to ensure rigour, all core research team members (SA, SJ, 
TW) will contribute to data analysis to ensure consistency 
in interpretation and a reflective research diary detailing 
the researcher’s role and impact on the study will be 
maintained.
Patient and public involvement
Following National Institute for Health Research (NIHR) 
guidance for involving people in research,58 59 this study 
has been developed through consultation and active 
collaboration with members of Swansea University Patient 
Experience and Evaluation in Research (PEER) and 
Cardiff University PPI group, who have been personally 
affected by cancer. Initially, members of the PEER group 
provided constructive feedback on the research idea 
and question, study population and design. PEER group 
representation on the project management team ensures 
continuing, active patient and public involvement at all 
stages of the research, including dissemination. Exam-
ples to date include offering feedback on the research 
protocol and ethics applications, acceptability of partic-
ipant information sheets and interview schedules and 
contributing to project team meetings. PPI membership 
of the project’s advisory group will contribute to strategic 
decisions including disseminating findings and routes to 
impact.
Ethics and dissemination
The proposed research will be performed in accordance 
with the UK Policy for Health and Social Care Research 
and Cardiff University Research Integrity and Gover-
nance Code of Practice (2018). The project was reviewed 
by the West Midlands and Black Country Research Ethics 
Committee in October 2019 and received a favourable 
opinion (REC ref: 19/WM/0299). The study is listed on 
the NIHR Clinical Research Network Central Portfolio 
Management System (study ID: 43946).
The dignity, rights, safety and well- being of partici-
pants will be the primary ethical considerations. Poten-
tial participants will be given sufficient time to read 
and consider study information and ask any questions. 
All participants who decide to participate will be asked 
to provide informed consent prior to taking part in the 
audio- recorded interview. Consent will be accepted via 
electronic completion and signature, and following 
Seymour,60 the researcher will use phrases such as ‘would 
it be okay if I asked about …’ to reaffirm consent during 
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the interview. The participant’s willingness to continue 
will also be checked at regular intervals.
Data collected from participants will be stored securely 
at Cardiff University. Completed consent forms will be 
stored on the university’s password- protected secure 
server in a location which is only accessible to the chief 
investigator (TW) and project researcher (SJ). The inter-
view audio- recordings will be uploaded onto the password- 
protected secure server at Cardiff University. Only the 
core research team (SA, SJ,TW) will be able to access the 
recordings. Once interview transcripts have been checked 
against corresponding audio- recordings, all identifiable 
information will be redacted and pseudonyms ascribed to 
all participants. All data will be securely stored after this 
study in accordance with Cardiff University policies, the 
General Data Protection Regulation (2016/679) and the 
Data Protection Act 2018.
Participants may benefit from knowing that their expe-
riences will be used to help inform service developments 
at individual and organisational levels and healthcare 
professional education, and thus potentially enhance 
the quality of person- centred care for people receiving 
cancer immunotherapy. The study findings may also facil-
itate knowledge transfer across different treatment sites, 
potentially benefiting wider patient groups. Knowledge 
transfer processes include outreach and collaboration 
with the study team developing collaborations with cancer 
centres to enhance the practitioner- focused relevance of 
the educational and training recommendations arising 
from analysis of data.
Although the research involves people affected by 
cancer, some of whom may have advanced disease, their 
participation in the study is unlikely to cause physical 
harm. However, there is an element of risk related to 
emotional distress. If this occurs, the researcher will 
stop recording immediately. Only if the participant is 
certain that they would like to resume, the interviewer 
will continue. After interviews, a ‘debrief’ space will 
mean that all participants will have the opportunity to 
talk to the researcher about the interview. For patient 
interviews, if any upsetting or unsettling feelings arose 
or are disclosed at this point, they will be signposted 
to local cancer support services. With permission, 
the person’s cancer key worker61 and consultant will 
be informed. For healthcare professional interviews, 
if any distress arises participants will be asked if they 
would like information about local NHS employee 
well- being support systems. Any signposting events will 
be logged in the study file.
Table 3 Application of Braun and Clarke49 50 six- step approach to thematic analysis
Step Description Example of application of thematic analysis step
1 Familiarising yourself with the data: Transcribing 
data, reading and re- reading the data, noting down 
initial ideas
Each interview will be transcribed, anonymised and subsequently 
read by all members of the core research team (initials redacted). 
During this process, initial notes regarding how the data might 
address the various study research questions will be made. 
At this stage, members of the core research team will meet to 
discuss initial impressions of the data.
2 Generating initial codes: Coding interesting features 
of the data in a systematic fashion across the entire 
dataset, collating data relevant to each code
The project researcher will generate initial codes based on the 
aforementioned discussions. The project researcher will draft 
an initial coding tree with examples of categories and codes. A 
recoding process will subsequently be undertaken, to ensure 
relevant data can be collated effectively and concisely.
3 Searching for themes: Collating codes into potential 
themes, gathering all data relevant to each potential 
theme
Categories and codes developed in the previous step will be 
discussed in meetings between members of the core research 
team. Codes will be altered and streamlined, and collated into 
potential themes.
4 Reviewing themes: Checking if the themes work in 
relation to the coded extracts and the entire data 
set, generating a thematic ‘map’ of the analysis
A comprehensive coding framework will be developed, with clear 
themes generated from the previous stage. These themes will be 
reviewed in discussions with the core research team. A thematic 
map will centre around the coding framework and illustrative data 
extracts.
5 Defining and naming themes: Ongoing analysis to 
refine the specifics of each theme, and the overall 
story the analysis tells, generating clear definitions 
and names for each theme
Key themes central to the analysis will be defined and named.
6 Producing the report: The final opportunity for 
analysis. Selection of vivid, compelling extract 
examples, final analysis of selected extracts, 
relating back the analysis to the research question 
and literature, producing a scholarly report of the 
analysis
Chapters will be constructed around the key themes developed 
in tep 5. Data extracts will be chosen carefully to support claims 
made.
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Findings will be reported in relevant, peer- reviewed and 
professional journals using accepted reporting criteria 
such as COnsolidated criteria for REporting Qualitative 
research (COREQ-32)62 to ensure transparency. A policy 
briefing highlighting key findings will be prepared and 
webinars facilitated to disseminate findings to partic-
ipants. The findings will be presented at relevant local, 
national and international conferences and healthcare 
professional education meetings.
DISCUSSION
There are a number of factors to consider relative to the 
study design. For instance, there are potential implica-
tions for the sample characteristic of using purposive 
and snowball sampling, as participating healthcare 
professionals are more likely to be self- selecting, 
engaged participants, and may even have more years 
of experience and seniority. However, it is feasible that 
this approach will ensure that the intended study popu-
lation is recruited to produce data which will enable 
us to address the research questions. As snowball 
sampling will likely lead to professionals identifying 
colleagues and known networks, this will potentially 
lead to some degree of bias in terms of work setting, 
level of experience. Patient participants will also likely 
to be affected by self- selection bias, even though they 
are to be identified and approached by clinicians. 
Self- selection bias in this instance might possibly be 
related to performance status, overall health and stage 
of disease, with patients who are generally more well 
and able to participate electing to participate in the 
interviews.
Differences in recruitment strategy will also poten-
tially affect analysis of data. The healthcare professionals’ 
population is feasibly more likely to represent a UK- wide 
perspective compared with patients, who are likely to be 
resident within travelling distance of the two oncology 
treatment centres, situated in Wales. The possible impli-
cations for the analysis are that findings from healthcare 
professionals are potentially more applicable to a UK- wide 
context. Experiences of immunotherapy treatment, the 
decision- making processes, associated treatment- related 
side effects are, however, likely to be translatable across 
regions within the UK. Within the analysis of data, the 
limitations of the variable recruitment strategies and 
resulting differences between population samples will be 
discussed.
The findings from this research will provide novel 
insights and in- depth, contextualised knowledge of 
cancer immunotherapy decision- making, the impact 
of treatments on people’s everyday lives, their needs 
and concerns and how they feel they might best be 
prepared and supported during treatment and beyond. 
It will explore healthcare professionals’ confidence and 
preparedness to provide safe, effective, proactive immu-
notherapy care and identify their support, education and 
training needs. Understanding people’s experiences may 
ultimately assist in the co- design of appropriate, effec-
tive supportive interventions to optimise the delivery of 
safe, effective and person- centred immunotherapy care. 
Furthermore, study findings may be used to inform 
and support the co- production of educational mate-
rials related to cancer immunotherapy and associated 
supportive care for healthcare professionals.
Current status of the study
Data collection commenced at the end of May 2020 and 
is ongoing.
Author affiliations
1School of Healthcare Sciences, Cardiff University, Cardiff, UK
2Chemotherapy Day Unit, Hywel Dda University Health Board, Haverfordwest, UK
3South West Wales Cancer Centre, Swansea Bay University Health Board, Swansea, 
UK
4PPI representative, Swansea, UK
5Department of Nursing, College of Human and Health Sciences, Swansea 
University, Swansea, UK
6Swansea Centre for Health Economics, College of Human and Health Sciences, 
Swansea University, Swansea, UK
Twitter Stephen Jennings @sjennings_01 and Tessa Watts @tesswatts15
Contributors SJ and TW: wrote the first draft of the manuscript. SA, JBu, AB, 
JBo, DFe and DFi: co- applicants of the grant that funds this study. TW, JBu and 
JBo: conceived and designed the study. JBu: Patient and Public Involvement 
representative who contributed to the study design. Every author contributed to the 
drafting of this manuscript.
Funding This study was supported by Macmillan Cancer Support (FO = 7165318).
Competing interests The research team includes individuals from various 
organisations, including Cardiff University, Swansea University, Hywel Dda 
University Health Board and Swansea Bay University Health Board. DFe reports an 
honorarium from Roche.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has 
not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been 
peer- reviewed. Any opinions or recommendations discussed are solely those 
of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and 
responsibility arising from any reliance placed on the content. Where the content 
includes any translated material, BMJ does not warrant the accuracy and reliability 
of the translations (including but not limited to local regulations, clinical guidelines, 
terminology, drug names and drug dosages), and is not responsible for any error 
and/or omissions arising from translation and adaptation or otherwise.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iDs
Stephen Jennings http:// orcid. org/ 0000- 0001- 5251- 3308
Sally Anstey http:// orcid. org/ 0000- 0003- 2295- 3761
Deborah Fenlon http:// orcid. org/ 0000- 0001- 7347- 891
Deborah Fitzsimmons http:// orcid. org/ 0000- 0002- 7286- 8410
Tessa Watts http:// orcid. org/ 0000- 0002- 1201- 5192
REFERENCES
 1 Zini EM, Lanzola G, Quaglini S, et al. Standardization of 
immunotherapy adverse events in patient information leaflets and 
development of an interface terminology for outpatients’ monitoring. 
J Biomed Inform 2018;77:133–44.









pen: first published as 10.1136/bm





8 Jennings S, et al. BMJ Open 2021;11:e043750. doi:10.1136/bmjopen-2020-043750
Open access 
 2 Maddams J, Utley M, Møller H. Projections of cancer prevalence in 
the United Kingdom, 2010-2040. Br J Cancer 2012;107:1195–202.
 3 Cavers D, Habets L, Cunningham- Burley S, et al. Living with and 
beyond cancer with comorbid illness: a qualitative systematic review 
and evidence synthesis. J Cancer Surviv 2019;13:148–59.
 4 Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events 
associated with immune checkpoint inhibitors: review of the 
literature. Eur J Cancer 2017;73:1–8.
 5 Fellner A, Makranz C, Lotem M, et al. Neurologic complications of 
immune checkpoint inhibitors. J Neurooncol 2018;137:601–9.
 6 Wang DY, Salem J- E, Cohen JV. Fatal toxic effects associated with 
immune checkpoint inhibitors: a systematic review and meta- 
analysis. JAMA Oncol 2018;4:1721–8.
 7 Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune- 
checkpoint inhibitors: epidemiology, management and surveillance. 
Nat Rev Clin Oncol 2019;16:563–80.
 8 Darvin P, Toor SM, Sasidharan Nair V, et al. Immune checkpoint 
inhibitors: recent progress and potential biomarkers. Exp Mol Med 
2018;50:1–11.
 9 Egen JG, Ouyang W, Wu LC. Human anti- tumor immunity: insights 
from immunotherapy clinical trials. Immunity 2020;52:36–54.
 10 Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated 
melanoma without BRAF mutation. N Engl J Med 2015;372:320–30.
 11 Ascierto PA, Long GV, Robert C, et al. Survival outcomes in patients 
with previously untreated BRAF wild- type advanced melanoma 
treated with nivolumab therapy: three- year follow- up of a randomized 
phase 3 trial. JAMA Oncol 2019;5:187–94.
 12 Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel 
in advanced squamous- cell non- small- cell lung cancer. N Engl J Med 
2015;373:123–35.
 13 Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of 
long- term survival data from phase II and phase III trials of 
ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 
2015;33:1889–94.
 14 Herbst RS, Baas P, Kim D- W, et al. Pembrolizumab versus docetaxel 
for previously treated, PD- L1- positive, advanced non- small- cell 
lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 
2016;387:1540–50.
 15 Reck M, Rodríguez- Abreu D, Robinson AG, et al. Pembrolizumab 
versus chemotherapy for PD- L1- positive non- small- cell lung cancer. 
N Engl J Med 2016;375:1823–33.
 16 Gandhi L, Rodríguez- Abreu D, Gadgeel S, et al. Pembrolizumab plus 
chemotherapy in metastatic non- small- cell lung cancer. N Engl J 
Med 2018;378:2078–92.
 17 Antonia SJ, Villegas A, Daniel D, et al. Overall survival with 
durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J 
Med 2018;379:2342–50.
 18 Brahmer JR, Rodríguez- Abreu D, Robinson AG, et al. Health- related 
quality- of- life results for pembrolizumab versus chemotherapy in 
advanced, PD- L1- positive NSCLC (KEYNOTE-024): a multicentre, 
international, randomised, open- label phase 3 trial. Lancet Oncol 
2017;18:1600–9.
 19 Petrella TM, Robert C, Richtig E, et al. Patient- reported outcomes 
in KEYNOTE-006, a randomised study of pembrolizumab versus 
ipilimumab in patients with advanced melanoma. Eur J Cancer 
2017;86:115–24.
 20 Harrington KJ, Ferris RL, Blumenschein G, et al. Nivolumab 
versus standard, single- agent therapy of investigator’s choice in 
recurrent or metastatic squamous cell carcinoma of the head and 
neck (CheckMate 141): health- related quality- of- life results from a 
randomised, phase 3 trial. Lancet Oncol 2017;18:1104–15.
 21 Schadendorf D, Larkin J, Wolchok J, et al. Health- related quality of 
life results from the phase III CheckMate 067 study. Eur J Cancer 
2017;82:80–91.
 22 Long GV, Atkinson V, Ascierto PA, et al. Effect of nivolumab on 
health- related quality of life in patients with treatment- naïve 
advanced melanoma: results from the phase III CheckMate 066 
study. Ann Oncol 2016;27:1940–6.
 23 Park R, Shaw JW, Korn A, et al. The value of immunotherapy for 
survivors of stage IV non- small cell lung cancer: patient perspectives 
on quality of life. J Cancer Surviv 2020;14:363–76.
 24 Levy D, Dhillon HM, Lomax A, et al. Certainty within uncertainty: a 
qualitative study of the experience of metastatic melanoma patients 
undergoing pembrolizumab immunotherapy. Support Care Cancer 
2019;27:1845–52.
 25 Ramos- Casals M, Brahmer JR, Callahan MK, et al. Immune- related 
adverse events of checkpoint inhibitors. Nat Rev Dis Primers 
2020;6:1–21.
 26 Ala- Leppilampi K, Baker NA, McKillop C, et al. Cancer patients’ 
experiences with immune checkpoint modulators: a qualitative study. 
Cancer Med 2020;9:3015–2022.
 27 Jamal S, Hudson M, Fifi- Mah A, et al. Immune- related adverse 
events associated with cancer immunotherapy: a review for the 
practicing rheumatologist. J Rheumatol 2020;47:166–75.
 28 Couey MA, Bell RB, Patel AA, et al. Delayed immune- related events 
(DIRE) after discontinuation of immunotherapy: diagnostic hazard of 
autoimmunity at a distance. J Immunother Cancer 2019;7:1–11.
 29 Parakh S, Cebon J, Klein O. Delayed autoimmune toxicity occurring 
several months after cessation of anti- PD-1 therapy. Oncologist 
2018;23:849–51.
 30 Wang DY, Salem J- E, Cohen JV, et al. Fatal toxic effects associated 
with immune checkpoint inhibitors: a systematic review and meta- 
analysis. JAMA Oncol 2018;4:1721–8.
 31 NHS England. Achieving world- class cancer outcomes: a strategy for 
England 2015–2020, 2016. Available: https://www. england. nhs. uk/ 
publication/ achieving- world- class- cancer- outcomes- a- strategy- for- 
england- 2015- 2020 [Accessed 17 Mar 2020].
 32 Scottish Government. Beating cancer: ambition and action, 2016. 
Available: https://www. gov. scot/ publications/ beating- cancer- 
ambition- action [Accessed 17 Mar 2020].
 33 Wales Cancer Network. Cancer delivery plan 2016-2020, 2016. 
Available: http://www. walescanet. wales. nhs. uk/ document/ 299783 
[Accessed 17 Mar 2020].
 34 de Boer SM, Powell ME, Mileshkin L, et al. Toxicity and quality of 
life after adjuvant chemoradiotherapy versus radiotherapy alone 
for women with high- risk endometrial cancer (PORTEC-3): an 
open- label, multicentre, randomised, phase 3 trial. Lancet Oncol 
2016;17:111–26.
 35 Schäfer R, Strnad V, Polgár C, et al. Quality- of- life results for 
accelerated partial breast irradiation with interstitial brachytherapy 
versus whole- breast irradiation in early breast cancer after breast- 
conserving surgery (GEC- ESTRO): 5- year results of a randomised, 
phase 3 trial. Lancet Oncol 2018;19:834–44.
 36 Huddart RA, Hall E, Lewis R, et al. Patient reported quality of life 
outcomes in patients treated for muscle- invasive bladder cancer with 
radiotherapy ± chemotherapy in the BC2001 Phase III randomised 
controlled trial. Eur Urol 2020;77:260–8.
 37 Schadendorf D, Dummer R, Hauschild A, et al. Health- related quality 
of life in the randomised KEYNOTE-002 study of pembrolizumab 
versus chemotherapy in patients with ipilimumab- refractory 
melanoma. Eur J Cancer 2016;67:46–54.
 38 Cella D, Grünwald V, Nathan P, et al. Quality of life in patients with 
advanced renal cell carcinoma given nivolumab versus everolimus 
in CheckMate 025: a randomised, open- label, phase 3 trial. Lancet 
Oncol 2016;17:994–1003.
 39 Harrington KJ, Ferris RL, Blumenschein G, et al. Nivolumab 
versus standard, single- agent therapy of investigator's choice in 
recurrent or metastatic squamous cell carcinoma of the head and 
neck (CheckMate 141): health- related quality- of- life results from a 
randomised, phase 3 trial. Lancet Oncol 2017;18:1104–15.
 40 Reck M, Rodríguez- Abreu D, Robinson AG, et al. Updated 
analysis of KEYNOTE-024: Pembrolizumab versus platinum- 
based chemotherapy for advanced non- small- cell lung cancer 
with PD- L1 tumor proportion score of 50% or greater. J Clin Oncol 
2019;37:537–46.
 41 Wong A, Billett A, Milne D. Balancing the hype with reality: what 
do patients with advanced melanoma consider when making the 
decision to have immunotherapy? Oncologist 2019;24:e1190–6.
 42 Milne D, Hyatt A, Billett A, et al. Exploring the experiences of 
people treated with immunotherapies for advanced melanoma 
and those caring for them: “real- world” data. Cancer Nurs 
2020;43:e97–104.
 43 Elwyn G, Laitner S, Coulter A, et al. Implementing shared decision 
making in the NHS. BMJ 2010;341:c5146.
 44 Kane HL, Halpern MT, Squiers LB, et al. Implementing and evaluating 
shared decision making in oncology practice. CA Cancer J Clin 
2014;64:377–88.
 45 Hack TF, Degner LF, Watson P, et al. Do patients benefit from 
participating in medical decision making? Longitudinal follow- up of 
women with breast cancer. Psychooncology 2006;15:9–19.
 46 Nelson A, Longo M, Byrne A. Chemotherapy decision- making in 
advanced lung cancer: a prospective qualitative study. BMJ Supp 
Pall Care.
 47 Fox JA, Langbecker D, Rosenberg J, et al. Uncertain diagnosis 
and prognosis in advanced melanoma: a qualitative study of the 
experiences of bereaved carers in a time of immune and targeted 
therapies. Br J Dermatol 2019;180:1368–76.
 48 Ihrig A, Richter J, Grüllich C, et al. Patient expectations are better for 
immunotherapy than traditional chemotherapy for cancer. J Cancer 
Res Clin Oncol 2020;146:3189–98.
 49 Braun V, Clarke V. Using thematic analysis in psychology. Qual Res 
Psychol 2006;3:77–101.









pen: first published as 10.1136/bm





9Jennings S, et al. BMJ Open 2021;11:e043750. doi:10.1136/bmjopen-2020-043750
Open access
 50 Braun V, Clarke V. Reflecting on reflexive thematic analysis. Qual Res 
Sport Exerc Health 2019;11:589–97.
 51 Silverman D. Interpreting qualitative data. 5th edn. London: Sage 
Publications, 2015.
 52 Health Research Authority. Guidance about COVID-19 for sponsors, 
sites and researchers [online], 2020. Available: https://www. hra. 
nhs. uk/ covid- 19- research/ covid- 19- guidance- sponsors- sites- and- 
researchers/ [Accessed 2 Jul 2020].
 53 Holstein JA, Gubrium JF. Inside interviewing: new lenses, new 
concerns. Thousand Oaks: Sage Publications, 2003.
 54 Malterud K, Siersma VD, Guassora AD. Sample size in qualitative 
interview studies: guided by information power. Qual Health Res 
2015;26:1753–60.
 55 Legard R, Keegan J, Ward K. Qualitative research practice: a guide 
for social science students and researchers. 3rd edn. London: Sage 
Publications, 2003.
 56 Kvale S, Brinkmann S. Interviews: learning the craft of qualitative 
research interviewing. 3rd edn. Los Angeles: Sage Publications, 
2015.
 57 Bryman A. Social research methods. 5th edn. Oxford: Oxford 
University Press, 2015.
 58 NIHR, Chief Scientist Office, Health and Care Research Wales, Public 
Health Agency. Uk standards for public involvement – better public 
involvement for better health and social care research. Available: 
https://www. heal than dcar eres earch. gov. wales/ uk- standards- public- 
involvement [Accessed 2 Jul 2020].
 59 The National Cancer Research Institute. Impact of patient, carer and 
public involvement in cancer research. Available: https://www. ncri. 
org. uk/ publication/ impact- of- patient- carer- and- public- involvement- 
in- cancer- research [Accessed 23 Mar 2020].
 60 Seymour JE. Critical moments - death and dying in intensive care. 
Buckingham: Open University Press, 2001.
 61 Welsh Government. Principles and guidance – key workers for cancer 
patients. Welsh Government: Cardiff, 2014.
 62 Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting 
qualitative research (COREQ): a 32- item checklist for interviews and 
focus groups. Int J Qual Health Care 2007;19:349–57.









pen: first published as 10.1136/bm
jopen-2020-043750 on 27 M
ay 2021. D
ow
nloaded from
 
